multicenter, USA - 19 Mar `18Aclaris Therapeutics: Topical Solution

Official title: An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo

In brief: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.

Ages eligible: 18 Years to 65 Years

Locations: Aclaris Investigator Site 

  • Encinitas, California, United States, 92024
  • Los Angeles, California, United States, 90036
  • Worcester, Massachusetts, United States, 01655
  • Dallas, Texas, United States, 75390
  • Lynchburg, Virginia, United States, 24501

Status: Unknown, not recruiting

Start date: March 19, 2018
Completion date: September 30, 2019

Identifier: ClinicalTrials.gov NCT03468855

Contacts: To learn more about this study, you or your doctor may contact Aclaris Therapeuitcs. Please refer to this study by its NCT number.